If you're researching growth hormone optimization in the UAE in 2026, you've almost certainly run into the same question every serious investigator asks: tesamorelin or MK-677? Both target the GH/IGF-1 axis. Both are routinely cross-shopped on peptide forums. But mechanistically, evidentially, and in terms of what UAE researchers can actually source today, they sit in two different universes. REVIVE LAB UAE — the leading peptides supplier in Dubai — stocks tesamorelin 5 mg and 10 mg vials in-stock with cold-chain courier for same-day delivery across Dubai Marina, JBR, Business Bay, Downtown, Palm Jumeirah, and JVC. This guide breaks down exactly how the two molecules compare so you can decide which belongs in your protocol.
The most important distinction is what each compound does to the pituitary.
Tesamorelin is a stabilized analog of growth hormone–releasing hormone (GHRH). It binds the GHRH receptor on somatotrophs in the anterior pituitary and amplifies the body's own pulsatile GH release. Because the pulses still pass through hypothalamic feedback (somatostatin), GH peaks remain physiological — high enough to drive IGF-1, low enough not to crush insulin sensitivity. Stanley et al. (2014) documented this directly: tesamorelin raised IGF-1 by ~80 ng/mL on average without breaking glycemic control.
MK-677 (ibutamoren) is something completely different. It's a non-peptide, orally bioavailable ghrelin receptor agonist. It bypasses GHRH entirely and mimics the hunger hormone ghrelin at the GHS-R1a receptor. That triggers GH release — but it also triggers everything else ghrelin does: appetite spikes, fluid retention, lethargy in some users, and a notable rise in fasting glucose documented in the Nass 2008 trial in Annals of Internal Medicine.
| Parameter | Tesamorelin (injectable) | MK-677 (oral) |
|---|---|---|
| Drug class | GHRH analog (peptide) | Ghrelin-mimetic / GHS-R1a agonist (non-peptide) |
| Route | Subcutaneous, 29G–31G insulin syringe | Oral capsule / liquid |
| GH pulse pattern | Pulsatile, physiological | Sustained elevation, blunted natural rhythm |
| Phase III VAT data | Yes — Stanley 2014, Falutz 2007/2010 | None published |
| IGF-1 increase | ~80 ng/mL (Stanley 2014) | ~40–60% baseline (Nass 2008) |
| Appetite effect | Neutral | Strong increase (ghrelin agonism) |
| Fluid retention | Mild / rare | Common, dose-dependent |
| Fasting glucose | Neutral over 26 wk | Elevated in Nass 2008 |
| Available at REVIVE LAB UAE | Yes — 5 mg & 10 mg vials, HPLC tested | Not stocked |
This is where the comparison stops being close. Tesamorelin is the only molecule of the two with a regulatory-grade phase III dataset. Stanley et al., published in 2014 in the Journal of Clinical Endocrinology & Metabolism and built on Falutz 2007 (NEJM) and Falutz 2010, demonstrated a reproducible ~15–18% reduction in visceral adipose tissue (VAT) over 26 weeks in HIV-associated lipodystrophy. That data package is what made tesamorelin the only GHRH analog with FDA approval for a fat-loss indication. There is no MK-677 equivalent.
MK-677 has shorter-duration trials (Murphy 1998, Nass 2008, Sigalos 2018 review) focused on lean-mass and bone-turnover markers, with mixed body-composition findings and consistent signals of appetite increase, fluid retention, and impaired glucose tolerance. For a UAE researcher targeting the stubborn visceral fat that sits behind belly hardness in men over 35, that evidence gap matters. REVIVE Peptides UAE built its tesamorelin line around exactly this use case.
Tesamorelin's research protocol is straightforward: reconstitute the lyophilized 5 mg or 10 mg vial with 3 mL of BAC water (bacteriostatic water), administer 1–2 mg subcutaneously each evening, refrigerate the reconstituted vial, and respect the ~28-day shelf life. A standard 1 mL insulin syringe with a 29G or 31G needle handles delivery painlessly. The peptide is research-use only under an IRB protocol — REVIVE LAB UAE ships research-grade material with HPLC certificates of analysis.
MK-677 protocols typically involve oral dosing 10–25 mg before bed, but the half-life (~24 hours) means the GH/IGF-1 elevation never really comes down. That's the trade-off ghrelin-mimetics force: convenience of an oral route in exchange for non-pulsatile signaling and the side-effect profile that comes with chronic ghrelin agonism.
REVIVE LAB UAE is the peptides supplier UAE researchers turn to when speed and discretion both matter. Orders placed before 2 PM Dubai time are dispatched same day by cold-chain courier. Delivery windows by area:
Payment options include card, bank transfer, and tesamorelin cash on delivery (COD) across Dubai, Abu Dhabi, and Sharjah. All shipments use anonymous, unbranded outer packaging — no peptide names, no logos, no return-address giveaways. The cold-chain courier maintains 2–8 °C transit conditions so vial integrity is preserved from REVIVE's UAE warehouse to your door.
REVIVE Peptides UAE is a UAE-based research peptides operation purpose-built for serious investigators. Every batch of tesamorelin shipped from our Dubai facility comes with a third-party HPLC certificate of analysis confirming >99% purity of the lyophilized powder. We hold both 5 mg and 10 mg tesamorelin vials in cold-chain stock so you don't wait on international transit, and our courier network has been operating across the seven emirates since 2024. Discreet packaging is the default, not an upgrade. If you're searching for legit peptides UAE, this is the lab.
REVIVE LAB UAE stocks tesamorelin 5 mg and 10 mg vials with cold-chain courier dispatch across Dubai (Marina, JBR, Business Bay, Downtown, Palm Jumeirah, JVC, Al Barsha, Mirdif), Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, Umm Al Quwain, and Al Ain. Order before 2 PM for same-day Dubai dispatch.
In published research data, tesamorelin is the only molecule with a phase III dataset (Stanley 2014, Falutz 2007/2010) showing ~15–18% reduction in visceral adipose tissue over 26 weeks. MK-677 has no comparable VAT trial and is associated with fluid retention and increased appetite in the published literature.
Yes. REVIVE Peptides UAE supports tesamorelin cash on delivery (COD) across Dubai, Abu Dhabi, and Sharjah, plus card and bank transfer. Packaging is discreet and unlabeled — no branding on the outer box.